Literature DB >> 20856165

Beneficial effect of erythropoietin on sensorimotor function and white matter after hypoxia-ischemia in neonatal mice.

Xiyong Fan1, Cobi J Heijnen, Michael A van der KOOIJ, Floris Groenendaal, Frank van Bel.   

Abstract

There are mixed reports on the neuroprotective properties of erythropoietin (EPO) in animal models of birth asphyxia. We investigated the effect of EPO on short- and long-term outcome after neonatal hypoxic-ischemic (HI) brain injury in mice and compared the effect of two different dose regimens of EPO. Nine-day-old mice were subjected to HI, and EPO was injected i.p. at 0, 24, and 48 h after HI in a dose of either 5 or 20 kU/kg. Paw preference in the cylinder rearing test (CRT) was used as a measure of sensorimotor function. Only in female mice, administration of EPO at 5 kU/kg but not 20 kU/kg improved sensorimotor function, reduced striatum atrophy and hippocampal lesion volume, and enhanced myelin basic protein (MBP) staining as determined at 4 and 9 wk after HI. In addition, at 72 h after HI, more Ki 67 cells were found in the subventricular zone and dentate gyrus after EPO 5 kU/kg treatment, indicating an increase in progenitor cell proliferation. In conclusion, EPO improves sensorimotor function after neonatal HI and protects against striatum atrophy, hippocampus injury, and white matter loss. The protective effect of EPO is dose-dependent and only present in females.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20856165     DOI: 10.1203/PDR.0b013e3181fcbef3

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  28 in total

1.  The effect of erythropoietin on the severity of retinopathy of prematurity.

Authors:  Y Kandasamy; P Kumar; L Hartley
Journal:  Eye (Lond)       Date:  2014-04-25       Impact factor: 3.775

2.  Erythropoietin Treatment Exacerbates Moderate Injury after Hypoxia-Ischemia in Neonatal Superoxide Dismutase Transgenic Mice.

Authors:  R Ann Sheldon; Christine Windsor; Byong Sop Lee; Olatz Arteaga Cabeza; Donna M Ferriero
Journal:  Dev Neurosci       Date:  2017-04-27       Impact factor: 2.984

Review 3.  Erythropoietin in stroke therapy: friend or foe.

Authors:  Rhonda Souvenir; Desislava Doycheva; John H Zhang; Jiping Tang
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

4.  Sex differences in cell genesis, hippocampal volume and behavioral outcomes in a rat model of neonatal HI.

Authors:  Jaylyn Waddell; Marie Hanscom; N Shalon Edwards; Mary C McKenna; Margaret M McCarthy
Journal:  Exp Neurol       Date:  2015-09-12       Impact factor: 5.330

5.  Alteration in Downstream Hypoxia Gene Signaling in Neonatal Glutathione Peroxidase Overexpressing Mouse Brain after Hypoxia-Ischemia.

Authors:  R Ann Sheldon; Raha Sadjadi; Matthew Lam; Russell Fitzgerald; Donna M Ferriero
Journal:  Dev Neurosci       Date:  2015-03-17       Impact factor: 2.984

6.  Evaluation of the therapeutic benefit of delayed administration of erythropoietin following early hypoxic-ischemic injury in rodents.

Authors:  M L Alexander; C A Hill; T S Rosenkrantz; R H Fitch
Journal:  Dev Neurosci       Date:  2013-01-10       Impact factor: 2.984

Review 7.  Cooling for newborns with hypoxic ischaemic encephalopathy.

Authors:  Susan E Jacobs; Marie Berg; Rod Hunt; William O Tarnow-Mordi; Terrie E Inder; Peter G Davis
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

8.  Erythropoietin signaling promotes oligodendrocyte development following prenatal systemic hypoxic-ischemic brain injury.

Authors:  Lauren L Jantzie; Robert H Miller; Shenandoah Robinson
Journal:  Pediatr Res       Date:  2013-09-03       Impact factor: 3.756

Review 9.  Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates.

Authors:  Amber M Messier; Robin K Ohls
Journal:  Curr Opin Pediatr       Date:  2014-04       Impact factor: 2.856

10.  Effects of combination therapy using hypothermia and erythropoietin in a rat model of neonatal hypoxia-ischemia.

Authors:  Annie Y Fang; Fernando F Gonzalez; R Ann Sheldon; Donna M Ferriero
Journal:  Pediatr Res       Date:  2012-10-19       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.